A research project that used CRISPR to make cassava resistant to mosaic virus instead allowed the virus to mutate and be passed down to the next generation.
There is not an easy-to-use countermeasure, undo button, or antidote for CRISPR.
Scientiists have embraced CRISPR’s ability to quickly and cheaply modify the genomes of popular model organisms, but now they are trying the tool on more-exotic species.
Researchers described a method of rendering CRISPR-Cas9 "immunosilent," potentially allowing the editing and repair of genes to be accomplished reliably and stealthily.
Scientists have long hoped CRISPR — a technology that allows scientists to make very precise modifications to DNA — could eventually help cure many diseases. And now scientists are taking tangible first steps to make that dream a reality.
Research demonstrates the feasibility of using type I CRISPR-Cas to effectively introduce a spectrum of long-range chromosomal deletions with a single RNA guide in human embryonic stem cells and HAP1 cells. Type I CRISPR systems rely on the multi-subunit ribonucleoprotein (RNP) complex Cascade to identify DNA targets and on the helicase-nuclease enzyme Cas3 to degrade DNA processively.
Scientists have developed a method to boost the efficiency of CRISPR gene editing in Duchenne muscular dystrophy, according to a study that could have implications for optimizing gene therapies for other diseases.
CRISPR has transformed many areas of biology but using this tool to enhance certain varieties of crops such as wheat and corn remains difficult because of the plants’ tough cell walls. Now, an agricultural company has solved that problem by using pollen from one genetically modified plant to carry CRISPR’s components into another plant’s cells.
Alex Kelly, BioFoundry’s 26-year-old lab manager, compares biotech to the birth of the computer, once cloistered in big corporations, now at everyone’s fingertips. Upskill the people in biotech, Kelly believes, and you’ll get disruption writ large, with a potentially massive payoff for the most disadvantaged.
Variations of the genome editor CRISPR have wowed biology labs around the world over the past few years because they can precisely change single DNA bases. But such “base editors” can have a serious weakness. A pair of studies published this week shows that one kind of base editor causes many unwanted—and potentially dangerous— “off-target” genetic changes.